LyndonKimMD

Oncology • New York, NY

Hematologic Oncology, Neuro-Oncology

Professor, Neurology, Medicine and Neurosurgery, Mount Sinai Hospital, New York, NY

Join to view full profile

Dr. Kim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kim's full profile

Already have an account?

Office
1 Gustave L Levy Place
Box 1137
New York, NY 10029
Phone+1 212-824-8579

Fax+1 212-824-2330

Education & Training

Massachusetts General HospitalFellowship, Neuro-Oncology, 1994 - 1997
Brown UniversityFellowship, Hematology and Medical Oncology, 1991 - 1994
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1989 - 1991
Brooklyn Hospital CenterInternship, Internal Medicine, 1988 - 1989
Yonsei University College of MedicineClass of 1985

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2008 - 2026
NY State Medical License 2018 - 2026
PA State Medical License 2010 - 2024
MD State Medical License 2002 - 2018
NC State Medical License 1997 - 2016
NJ State Medical License 1990 - 2007

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Start of enrollment: 2012 Nov 09
Completed
Phase 1
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Start of enrollment: 2013 May 01
Completed
Phase 2
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Withdrawn
Phase 1
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Start of enrollment: 2015 Jan 30
Completed
Phase 1
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Active, not recruiting
Not Applicable
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1212 citations
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl, Lyndon Kim, Kraig Moore, Paul Duic, Cheryl Royce
Journal of Clinical Oncology. 2009-02-10
195 citations
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M Liau, Keyoumars Ashkan, David D Tran, Jian L Campian, John E Trusheim
Journal of Translational Medicine. 2018-05-29
169 citations
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A P...
Linda M Liau, Keyoumars Ashkan, Steven Brem, Jian L Campian, John E Trusheim
JAMA Oncology. 2023-01-01

Press Mentions

Northwest Biotherapeutics: Data Is Done, Just Wait for ApprovalNovember 23rd, 2022